Filing Flows › Neogenomics (NEO) › R&D spending
Neogenomics (NEO) R&D spending by quarter
Neogenomics' R&D spending was $9.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $8.7M (Q3 2025) to $10.8M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.9M | -8% | +13% |
| Q2 2026 | $10.8M | +13% | +19% |
| Q1 2026 | $9.5M | +4% | -6% |
| Q4 2025 | $9.2M | +6% | — |
| Q3 2025 | $8.7M | -4% | — |
| Q2 2025 | $9.0M | -11% | — |
| Q1 2025 | $10.2M | — | — |
Q3 2026 at a glance
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neogenomics' R&D spending?
Neogenomics' R&D spending was $9.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Neogenomics' R&D spending changed?
Over the last 7 quarters it ranged from $8.7M (Q3 2025) to $10.8M (Q2 2026).